Acute Migraine Management with Sumatriptan 6 mg Subcutaneous Autoinjector

Prescription Recommendations

• Prescribe a 6 mg subcutaneous sumatriptan autoinjector to be self‑administered at migraine onset, together with an NSAID (e.g., naproxen 500 mg or ibuprofen 400 mg) for optimal efficacy. 1, 2
• Instruct patients to inject a single 6 mg dose subcutaneously as soon as moderate‑to‑severe headache pain begins. 1, 2, 3

Combination Therapy (First‑Line Acute Treatment)

• The 2025 American College of Physicians (ACP) guideline strongly recommends adding a triptan to an NSAID (or to acetaminophen when NSAIDs are contraindicated) for patients who do not achieve relief with NSAID monotherapy. 1, 2
• Patients should take the triptan and NSAID simultaneously at migraine onset to maximize therapeutic benefit. 1, 2

Dosing and Administration

• A 6 mg subcutaneous dose is the standard regimen for acute migraine and cluster headache. 3
• Early administration (as soon as headache begins) improves response rates compared with delayed dosing. 1, 2

Medication‑Overuse Headache (MOH) Prevention

• Counsel patients that overuse of acute migraine medications can lead to chronic daily headache. 1, 2
• When attacks remain frequent despite optimal acute therapy, initiate preventive treatment (e.g., CGRP monoclonal antibodies, topiramate, propranolol). 1, 2, 3

Contraindications and Safer Alternatives

• Do not prescribe sumatriptan to patients with cardiovascular disease (including coronary artery disease, prior myocardial infarction, uncontrolled hypertension, or arrhythmias). 3
• For patients with cardiovascular contraindications, use CGRP receptor antagonists (gepants) such as rimegepant or ubrogepant instead. 1, 2

Special Populations

• Breastfeeding: Discuss potential risks and benefits of sumatriptan with the patient before prescribing. 1, 2
• Severe nausea/vomiting: Subcutaneous sumatriptan is preferred because it bypasses the gastrointestinal tract; add an antiemetic (e.g., metoclopramide or prochlorperazine) as needed. 1, 2

Medications Explicitly Contraindicated for Acute Migraine

• The 2025 ACP guideline strongly advises against prescribing opioids or butalbital‑containing products for acute migraine attacks. 1, 2

Alternative Acute Therapies When Sumatriptan Fails

• CGRP antagonists (gepants): Rimegepant 75 mg, ubrogepant 50–100 mg, or intranasal zavegepant 10 mg are recommended for patients who cannot tolerate or do not respond to triptan + NSAID therapy. 1, 2
• Dihydroergotamine (DHE): Intranasal or intravenous DHE may be used as rescue therapy. 1, 2
• Lasmiditan 50–100 mg: Reserved for patients who have exhausted other acute treatment options. 1, 2

Contraindication of Butalbital‑Containing Products and Evidence‑Based Acute Migraine Management

Guideline Recommendations

• The 2025 American College of Physicians guideline explicitly advises against the use of opioids or butalbital for acute episodic migraine. [4]
• The 2024 VA/DoD guideline similarly discourages any butalbital‑containing compounds for migraine treatment. [5]

Risks Specific to Butalbital

• Medication‑overuse headache (MOH) threshold: Regular use of butalbital on ≥10 days per month is strongly associated with development of MOH and progression to chronic migraine. [4]

First‑Line Acute Migraine Therapy

• Moderate‑to‑severe attacks: Initiate a triptan (e.g., sumatriptan, rizatriptan, etc.) combined with an NSAID (e.g., ibuprofen, naproxen, aspirin, diclofenac, or celecoxib) as early as possible after symptom onset. This regimen is recommended as the primary acute treatment. [4]
• Mild attacks: Use an NSAID alone, acetaminophen alone, or an NSAID + acetaminophen. [4]
• Aspirin‑acetaminophen‑caffeine (without butalbital): Receives a “strong for” recommendation with a number needed to treat of 9 for achieving pain freedom at 2 hours. [5]

Second‑Line and Rescue Options

• CGRP antagonists (gepants – rimegepant, ubrogepant, zavegepant): Recommended for patients who fail or cannot tolerate the triptan‑NSAID combination. [4]
• Dihydroergotamine (ergot alkaloid): Suggested as an alternative rescue medication when first‑line agents are ineffective or contraindicated. [4]
• Lasmiditan (ditan): Reserved for patients who have exhausted all other acute therapeutic options. [4]

Recognition of Medication‑Overuse Headache

• Clinicians should consider MOH when chronic headache persists despite treatment, recognizing that overuse of butalbital‑containing products may be the underlying cause. [4]

Special Populations

• Pregnancy: Acetaminophen is the safest acute migraine medication; NSAIDs may be used before the third trimester, and sumatriptan can be considered when the anticipated benefit outweighs potential risk. [6]
• Cardiovascular disease: Triptans should be avoided; CGRP antagonists (gepants) are preferred alternatives. [6]
• Elderly (≥65 years): Acetaminophen‑caffeine combinations (without butalbital) may be used, although supporting evidence is limited. [7]

First‑Line Antiemetic Strategy for Migraine‑Associated Nausea

Choice of Antiemetic

• Metoclopramide 10 mg is recommended as the first‑line antiemetic for migraine‑associated nausea and should be given together with the acute migraine regimen (triptan + NSAID or acetaminophen) to improve symptom control and drug absorption. 8, 9

Indications for Adding an Antiemetic

• In patients with severe nausea or vomiting that prevents reliable oral drug intake, a non‑oral triptan should be combined with an antiemetic to ensure effective migraine treatment. 8, 9

Acute Migraine Treatment Algorithm (Cited Recommendations)

• Mild migraine without significant nausea – treat with NSAID or acetaminophen alone; an antiemetic is not required. 8, 9
• Moderate‑to‑severe migraine with mild nausea – administer a triptan plus NSAID (or acetaminophen) together with metoclopramide 10 mg taken orally at migraine onset to provide dual relief of headache and nausea and to enhance gastrointestinal absorption of the migraine medications. 8, 9

Evidence strength for these recommendations was not explicitly graded in the cited sources.

Acute Combination Therapy for Adolescent Migraine

Recommended First‑Line Combination

• The 2020 pediatric migraine guidelines recommend that adolescents initiate acute treatment with rizatriptan taken simultaneously with ibuprofen (or acetaminophen when NSAIDs are contraindicated) at the onset of a moderate‑to‑severe migraine attack. 10

Dosing Recommendations

• For a typical 15‑year‑old patient, the suggested dose of ibuprofen is 10 mg/kg (approximately 400–600 mg), while acetaminophen may be used at 15 mg/kg (approximately 650–1000 mg) if ibuprofen is unsuitable; rizatriptan is prescribed at 5 mg or 10 mg per attack. All agents should be administered together at migraine onset. 10

Timing and Frequency Limits

• Early treatment—administering the combination as soon as moderate headache begins—provides superior pain relief compared with delayed dosing. 10
• The total daily rizatriptan dose should not exceed 30 mg (maximum three 10‑mg doses), and doses must be spaced at least 2 hours apart. Acute medication use should be limited to fewer than 10 days per month to avoid medication‑overuse headache. 10

Safety and Tolerability

• Controlled trial data indicate that the rizatriptan + acetaminophen combination is as well tolerated as either drug alone, with no clinically relevant drug‑drug interactions identified between rizatriptan and NSAIDs or acetaminophen. The FDA label for rizatriptan does not list these agents as contraindicated. 10

Situations Requiring Avoidance of the Combination

• The combination should be avoided in patients concurrently using propranolol (dose of rizatriptan limited to 5 mg, maximum 15 mg/24 h), those who have taken ergotamine‑type agents or another triptan within the preceding 24 hours, or those receiving MAO‑inhibitors. 10

Alternative Strategies When the Initial Combination Fails

• If the rizatriptan‑NSAID regimen is ineffective after 2–3 treated attacks, clinicians should consider switching to a different triptan (e.g., sumatriptan nasal spray or zolmitriptan nasal spray) combined with an NSAID, or using non‑oral triptan formulations for rapid pain spikes. Adding an antiemetic such as metoclopramide (10 mg) is advised when nausea is prominent. 10

Indications for Initiating Preventive Therapy

• Adolescents who require acute treatment ≥2 times per month and experience ≥3 days of disability should be started on preventive medication (e.g., propranolol, topiramate, or amitriptyline) together with cognitive‑behavioral therapy. Frequent attacks shortly after starting a triptan may already meet criteria for preventive therapy. 10

Management of Sumatriptan Treatment Failure

Alternative Acute Therapies

• When sumatriptan does not provide adequate relief after 2–3 treated migraine attacks, the recommendation is to switch to another triptan (e.g., rizatriptan, eletriptan, or zolmitriptan) and combine it with an NSA ID for improved efficacy. This guidance is based on evidence reported in Annals of Internal Medicine (2024) 11.

Evidence‑Based Acute Rescue Options for Severe Migraine

Greater Occipital Nerve Block (GONB)

• Offer a greater occipital nerve block as a Level A rescue option for severe migraine when rapid relief is needed without systemic medication exposure; it can be performed in the emergency department or an outpatient clinic and requires fewer resources than intravenous therapy. 12

Lasmiditan

• Reserve oral lasmiditan 50–100 mg for patients whose migraine attacks have failed to respond to all other acute treatments; it is considered a last‑resort agent because of its adverse‑effect profile, which includes driving restrictions. 12